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SUMMARY 
Title: Newly diagnosed diabetes - treatment plan and goals 
Author: Abdelkarim Al-Jabiri 
Diabetes mellitus is a chronic disease in which the people who suffer from it are forced to 
change the whole dynamic of their lives. It has epidemic proportions and there is virtually no 
country that is not struggling against rising numbers of diabetes cases.  
This thesis is a short review on the topic of ―Newly diagnosed diabetes- treatment plan and 
goals‖. It covers the general overview on diabetes mellitus types. Covering signs and 
symptoms, aetiology, epidemiology, pathophysiology, diagnosis and treatment plan and goals 
of the main two types of diabetes.  
Diabetes type 2 represents about 90% of diabetes cases, diabetes type 1 represents about 5% 
and other rare types represent the rest. The current most common treatment options and 
further management goals for DM type 2 are lifestyle modifications followed with non-insulin 
hypoglycaemic agents later requiring subcutaneous insulin injections. In DM type 1 the 
mainstay of treatment is subcutaneous insulin injections and further management is highly 
dependent on education of patients to have satisfactory control of BGs to reduce the risk of 
long term complications.  
WHO gives the criteria on how to diagnose and differentiate diabetes types which helps 
clinicians worldwide to accurately diagnose diabetes. At the end a short presentation of some 
less known types of diabetes that still need more attention and more research. 
Key words: diabetes mellitus, types, diagnosis, treatment. 
  
SAŢETAK 
Naslov: Novo dijagnosticirana šećerna bolest – plan i ciljevi liječenja 
Autor: Abdelkarim Al-Jabiri 
Šećerna bolest je kronična bolest u kojoj su ljudi koji pate od nje prisiljeni promijeniti cijelu 
dinamiku svog ţivota. Ima razmjere epidemije i praktički nema zemlje koja se ne bori protiv 
povećanja broja slučajeva dijabetesa.  
 
Ovaj diplomski rad je kratki pregledni rad na temu ―Novo dijagnosticirana šećerna bolest – 
plan i ciljevi liječenja‖. Ovaj rad pokriva generalni pregled raznih tipova diabetesa mellitusa. 
Pokriveni su znaci i simptomi, etiologija, epidemiologija, patofiziologija, dijagnoza te plan i 
ciljevi liječenja dva glavna tipa dijabetesa.  
 
Dijabetes tipa 2 predstavlja oko 90% slučajeva dijabetesa, dijabetes tipa 1 predstavlja oko 5%, 
a ostali rijetki tipovi predstavljaju ostatak. Sadašnje najčešće opcije liječenja i daljnji ciljevi 
upravljanja za DM tip 2 su promjene načina ţivota, a potom ne- inzulinski hipoglikemijski 
lijekovi koji kasnije traţe subkutane injekcije inzulina. U DM tip 1 glavno je liječenje 
subkutanim injekcijama inzulina, a daljnje upravljanje visoko ovisi o obrazovanju pacijenata 
da imaju zadovoljavajuću kontrolu BG-ova kako bi se smanjio rizik dugoročnih komplikacija.  
 
WHO daje kriterije o dijagnosticiranju i razlikovanju tipova dijabetesa koji pomaţu 
kliničarima diljem svijeta da precizno dijagnosticiraju dijabetes. Na kraju je kratko 
prezentirano dvoje manje poznatih tipova dijabetesa koji još trebaju više paţnje i više 
istraţivanja. 
Ključne riječi: dijabetes mellitus, tipovi, dijagnoza, liječenje
1 
 
1. Introduction 
Diabetes is a big health concern all over the world. Impacting not only the overall health of 
the population but presents as a big economic problem both through health expenditures and 
days of lost work. It does not concern only one specialty but requires a multidisciplinary 
approach. Problem of diabetes is shown not only through an increase in number of patients 
but also in the decreasing age at which people acquire diabetes. Diabetes is a chronic disease 
which affects a big part of the human population. IDF states (1) that more than 425 million 
people suffer from diabetes worldwide.  
People with diabetes have either destruction of their pancreatic beta cells rendering them 
unable to produce insulin or unable to utilize the endogenous insulin created by their bodies. 
Insulin is a hormone in the human body produced by the pancreatic beta cells that lowers 
glucose in blood. Its action is opposite of glucagon produced by pancreatic alpha cells which 
raises blood glucose levels. Diabetes is a serious lifelong disease with serious consequences.  
WHO states: ―Diabetes caused 1.5 million deaths in 2012. Higher-than-optimal blood glucose 
caused an additional 2.2 million deaths, by increasing the risks of cardiovascular and other 
diseases. Forty-three percent of these 3.7 million deaths occur before the age of 70 years. The 
percentage of deaths attributable to high blood glucose or diabetes that occurs prior to age 70 
is higher in low- and middle-income countries than in high-income countries.‖(2)  
Diabetes is most commonly divided into three main types. Diabetes type 1, diabetes type 2 
and gestational diabetes. Diabetes has both acute and chronic consequences. Acute 
consequences usually entail patients using subcutaneous injections of insulin that exposes 
them to the risk of administering too many units of insulin and entering a hypoglycaemic 
state. Hypoglycaemia can lead to a diabetic coma which is a severe state where the patients 
lose consciousness and cannot be awakened. Prolonged state of coma and hypoglycaemia can 
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lead to serious glucose deficiency in the brain sometimes causing brain damage or even lead 
to a fatal outcome. Chronic consequences are usually caused by inadequate blood glucose 
level control where patients have persistent high blood sugar levels. Persistent 
hyperglycaemia in patients causes many organs to be at risk of many different pathologies 
especially microvasculature and nerves. ―The prolonged hyperglycaemia leads to heart 
attacks, strokes, kidney failure, leg amputation, vision loss and nerve damage.‖(2)  
Diabetes in pregnancy or gestational diabetes has to be adequately controlled to avoid damage 
to the unborn foetus. The trend of acquiring diabetes is unfortunately increasing and it is not 
showing any signs of slowing down. Diabetes is a life long illness that doesn’t only affect 
people that suffer from it but the society as a whole. 
2. Classification 
Currently diabetes is divided into following four main divisions (3). First being diabetes type 
1, second is diabetes type 2, third gestational diabetes and other specific types. Diabetes type 
1 can be further subdivided into immune mediated and idiopathic types. Type 2 diabetes has 
no subdivisions but can range from patients unable to utilize their endogenous insulin to 
patients having combined inability to both produce and utilize endogenous insulin. 
Gestational diabetes occurs in pregnancy and may or may not disappear after the end of 
pregnancy. Other specific types encompass a wide range of possible pathologies. Genetic 
defects of beta cell function and/or insulin action. Possible pathologies of the exocrine 
pancreas. Endocrinopathies that adversely affect BG. Iatrogenic causes of diabetes. 
Monogenetic diabetes which is a consequence of a mutation of a specific gene (called MODY 
for historical reasons). Infections increasing the risk of acquiring diabetes. Some less common 
forms of immune mediated diseases may exist. Many genetic syndromes are also associated 
with diabetes.  
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In the past it was considered that there is a clear demarcation between diabetes type 1 and 
diabetes type 2. Diabetes type 1 was usually assumed to be a disease reserved for the 
paediatric population, while on the other hand diabetes type 2 was considered to be a disease 
affecting the older population.  
As more time passed it was becoming obvious that the classification is lacking. The age 
boundary between the previously considered two completely different diseases with vast 
differences in their epidemiologic data started to blur. We see an increase in both the overall 
numbers of affected patients with both diseases and especially a rise in diabetes type 2 
occurring more and more in the younger population of patients. 
This thesis will mainly focus on type 1 and 2 diabetes, MODY (maturity onset diabetes of the 
young) and LADA (latent autoimmune diabetes in adults).  
3. Diabetes mellitus type 1 
Diabetes type 1 is a subtype of DM where patients cannot produce insulin due to destruction 
of beta cells of the pancreas so they need treatment with exogenous insulin. Insulin was 
previously extracted from cattle pancreas, but nowadays it is produced by recombinant DNA 
technology which enabled the creation of insulin analogues with more appropriate 
pharmacodynamics.  
Treatment with insulin can be administered through subcutaneous injections with insulin 
syringes, pens or infused by pumps that have cartridges filled with insulin that is administered 
through cannulas that are placed likewise subcutaneously and can be used for up to two 
weeks. 
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3.1 Signs and symptoms 
Polyuria (increased urination), polydipsia (increased thirst), dry mouth, polyphagia (increased 
hunger), fatigue, and weight loss constitute some of the most often encountered signs and 
symptoms in patients presenting with diabetes mellitus type 1 (2).  
These signs and symptoms although obvious and usually point to a specific disease for 
medical professionals to the general public are quite unspecific and don’t elicit much 
discomfort. Although the age at which any diabetes type can occur is not so obvious anymore 
it is still more common to present in the paediatric population so these symptoms usually get 
attributed to children drinking a lot of water or too many juices. For those reasons patients 
tend not to seek medical help until they start suffering from consequences of diabetic 
ketoacidosis.  
Diabetic ketoacidosis is a state that the body enters because of lack of insulin that stops 
utilization of glucose. Additionally glucagon further raises already high blood glucose levels 
even further and since we lack insulin, free fatty acids get released from adipose tissues then 
converted via beta oxidation to ketone bodies and they start being used as energy source for 
the metabolism. This in turn diminishes blood pH which leads to a state of metabolic acidosis.  
Signs and symptoms of diabetic ketoacidosis are the following: (4): ―dry skin, rapid deep 
breathing, drowsiness, increased thirst, frequent urination, abdominal pain, and vomiting‖. 
3.2 Aetiology 
Although almost 100 years passed since the first use of insulin in diabetic patients and we 
made great improvements in management and treatment of those patients, we still don’t know 
the exact aetiology of diabetes mellitus type 1. Many studies have been done to try and 
discover what is causing DM type 1.  
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So far we have two main animal models used in scientific literature trying to describe the 
processes leading to the disease, the non-obese diabetic mouse and the BioBreeding-diabetes 
prone rat (5). Most studies show that the aetiology must be multifactorial and that the process 
that leads to DM type 1 is not a simple one. Autoimmune reaction towards pancreatic beta 
cells leading to their destruction results in inability to control BGs.  
It is postulated so far that there are many components triggering the autoimmune response 
such as genetic susceptibility, environmental factors and also some chemicals and drugs that 
have implications in DM type 1. Pociot and Lernmark (6) in their research of genetic factors 
involved in DM type 1 state that the primary risk factor for autoimmunity of beta cells is 
genetic. Patients with either HLA-DR3-DQ2 or HLA-DR4-DQ8 haplotypes, or both, seem to 
have an increased risk of developing DM type 1 but an environmental trigger is usually 
required.  
Oxford handbook of endocrinology and diabetes explains us the risk of acquiring DM type 1. 
The lifetime risk of developing DM type 1 in the Caucasian population is below 1%. Further 
strengthening the claim that genes are responsible for DM type 1 is the increased risk of 
acquiring the disease if one of the family members is already affected by it. Risk rises to 
about 2% if the mother has it, while if the father has it risk is about 4% and affected siblings 
raise it to about 5%. Even in monozygotic twins the occurrence rate is about 50% by age 40. 
(7) 
There are many things to take into account when talking about possible causes of DM type 1 
but it seems that many do agree on the fact that environmental factors have a significant role 
to play in developing the disease as well as genetic factors. Knip et al. explain the following: 
―A series of evidence supports a critical role of exogenous factors in the development of type 
1 diabetes, such as 1) the fact that <10% of individuals with HLA-conferred diabetes 
susceptibility do progress to clinical disease, 2) a pairwise concordance of type 1 diabetes of 
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<40% among monozygotic twins, 3) a more than 10-fold difference in the disease incidence 
among Caucasians living in Europe, 4) a several-fold increase in the incidence over the last 50 
years, and 5) migration studies indicating that the disease incidence has increased in 
population groups who have moved from a low-incidence to a high-incidence region. (8)‖ 
Similarly, Oilinki et al. described in their research the prevalence of DM type 1 between 
Somali and Finish children living in Finland. They showed although the incidence of DM type 
1 in Somalia is rather low, these children in the same geographical location showed similar 
frequency of DM type 1 maybe owing to certain environmental factors involved. (9)  
Other possible causes can sometimes be more obvious in some patients. These are trauma to 
the pancreas, possible complications of pancreatitis, tumours and some antineoplastic agents 
like Streptozotocin. Streptozotocin is used in inducing DM type 1 in animal models because 
of its selective beta cell toxicity. Possible use is also in treatment of metastatic cancer of 
pancreatic islet cells that otherwise cannot be treated by surgery. (10) 
3.3 Epidemiology 
Talking about diabetes in general we see that it has pandemic proportions and there is 
basically no country that is not affected by this disease. About 5-10% of diabetes cases can be 
classified as DM type 1 (11).  
Further supporting the idea of environmental factors being involved in aetiology of DM type 
1 are national registries for newly diagnosed cases of diabetes. What these registries show like 
the WHO DIAMOND project is that some countries have an incidence as high as 60 cases per 
100 000 annually while some have as low as 0.5 cases per 100 000 annually in children aged 
under 15 (2).  
East Asian and Native American populations have low incidences about 0.4 cases per 100 000 
annually, while the highest rates are found in Finland with more than 60 cases per 100 000 
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annually, Sardinia shows around 40 cases per 100 000 annually, and Sweden 47 per 100 000 
annually. The risk seems to be highest in European high income countries (12). The incidence 
for the country of Croatia is around 8 cases per 100 000 annually (13). These differences can 
be further exemplified by having different genetic makeup, HLA haplotypes in different 
countries. 
3.4 Pathophysiology 
Destruction of beta cells of the pancreas is the cause of DM type 1 no matter what risk factors 
or triggers we consider. Autoimmune response towards the beta cells seems to be the 
generally accepted process by which the destruction occurs. This autoimmunity seems to be 
caused by autoreactive CD4+ T helper cells and CD8+ T cells, autoantibody-producing B 
cells and activation of the innate immune system (14).  
There are researches that postulate that the causative agent or at least a trigger to the 
autoimmunity might be a bacteria. When talking about bacterial infections they explain that 
these bacteria infiltrate the pancreas through the ampulla of Vater from the gastrointestinal 
system. Possible causative agents are postulated to be E. Coli, Enterococcus and S. Aureus. 
After the initial infiltrated beta cells are destroyed the remaining beta cells seem to succumb 
to a big glucose load and toxicity that they need to manage which in turn leads to more beta 
cell destruction and ultimately to diabetes (15).  
Pociot and Lernmark explain that the pathogenesis can be divided into three different stages: 
―1, appearance of β-cell autoimmunity, normoglycaemia, and no symptoms; 2, β-cell 
autoimmunity, dysglycaemia, and no symptoms; and 3, β-cell autoimmunity, dysglycaemia, 
and symptoms of diabetes. (6)‖.  
The last thing that needs explaining is the so called honeymoon period. This period occurs 
when the patient with DM type 1 starts the insulin treatment. After they start the treatment 
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they seem to have better insulin levels for a period of time. This is believed to be due to 
dysregulation in their immunity (16). 
3.5 Diagnosis 
Most common presentation of DM type 1 is polyuria (excessive urination), polydipsia 
(excessive thirst), and polyphagia (excessive eating or appetite). Nausea, tiredness and blurred 
vision also occur. All of these symptoms occur from hyperglycaemia.  
When these symptoms are recognized the first pathology that comes to mind especially if 
coupled with a younger patient is DM type 1. To diagnose DM WHO recommends three 
different options for testing if the patient has the disease. Fasting plasma glucose, 2-h plasma 
glucose in OGTT and HbA1c.  
Fasting plasma glucose is a test used by doctors to assess the concentration of glucose in 
blood after an 8 to 10 hour fasting period. In these 8 to 10 hours patients are instructed to not 
eat or drink anything except water. 2-h plasma glucose test or sometimes referred to as 2-h 
glucose tolerance test is performed in such a way that the patient intakes an oral dose of 75g 
of glucose. Dose is adjusted for adult patients below 42 kg of weight and for children. Venous 
blood is drawn 2 hours after ingestion to measure BG. HbA1c or glycated haemoglobin of 
6.5% or more is diagnostic for DM. HbA1c value is commonly used in diabetes and can give 
a longer estimate of glucose levels in time over a period of three months- erythrocyte lifespan. 
It is necessary to have at least two positive values to diagnose DM. 
Based on these tests and their results current WHO diagnostic criteria are divided into three 
different results (2). Impaired fasting glucose, impaired glucose tolerance and diabetes. 
Patient is said to have impaired fasting glucose if his fasting plasma glucose shows 6.1 to 6.9 
mmol/L (110 mg/dl to 125 mg/dl) and if measured complementing this would be 2-h plasma 
glucose result of < 7.8 mmol/L (140 mg/dl). Impaired glucose tolerance criteria are fasting 
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plasma glucose of < 7.0 mmol/L (126 mg/dl) and 2-h plasma glucose of ≥ 7.8 and < 11.1 
mmol/L (140 mg/dl and 200 mg/dl). Diabetes criteria are fasting plasma glucose of ≥ 7.0 
mmol/L (126 mg/dl) or 2-h plasma glucose of ≥ 11.1 mmol/L (200 mg/dl) or HbA1c of ≥ 
6.5% (48 mmol/mol).  
3.6 Treatment plans and goals 
Treatment of DM type 1 usually starts when it is discovered that the patient suffers from the 
disease. As previously explained usual presentation is one of polyuria, polydipsia and 
polyphagia. This presentation is however most common one and does not occur in every 
patient. The discrepancy between the usual presentation and some less common ones can 
affect the timing when DM type 1 is recognized. This most commonly occurs in paediatric 
population. Due to this delay in diagnosis many patients present with diabetic ketoacidosis.  
Treatment of DKA is not simple and especially so in the younger patients. Consensus 
statement from ADA explains that the main points to consider in treating DKA is fluid and 
electrolyte replacement, insulin therapy, potassium and phosphate depletion, and acidosis 
(17).  
Once the patient is stabilized and the risk of cerebral oedema and recurrence of DKA has 
lessened the patient is started on subcutaneous insulin injections. This initial point of 
treatment of DKA should be performed in specialized wards. During the hospital stay the 
education of patient parents and/or patients themselves begins. Education has to envelop as 
many aspects of the disease as possible to enable the patients and/or their parents to have a 
normal lifestyle. Although we strive to do the best we can, patients still have an enormous 
amount of information to process in combination with the psychological stress that they are 
suffering from a chronic disease that is going to affect them their whole life. Beginning of the 
education starts with the explanation of the disease itself. Newly diagnosed patients and their 
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families are naturally going to have many questions that need to be explained and elaborated 
to them to prepare them for their future.  
Important aspect of managing diabetes is measuring the blood glucose levels. Patients need to 
be taught how to utilize blood glucose measuring devices to monitor their glucose. Another 
way of measuring glucose is with continuous glucose monitors. These monitors have glucose 
sensors that are placed subcutaneously and can give blood glucose measurement at any time. 
Although still not completely perfected more and more patients are opting for these devices 
since they bypass the need to have their fingers pricked on multiple occasions during the day.  
Another important aspect of treatment is the actual management of glucose. First line of 
treatment are subcutaneous insulin injections that serve as a replacement for their endogenous 
insulin that they are unable to produce. Insulin can be divided into rapid, short, intermediate, 
and long acting types. Different types of insulin are combined to ensure the best possible 
glycaemic control. The long term goal is to keep the value of HbA1c below 6.5% (48 
mmol/mol). Higher levels of HbA1c are tolerated in elderly patient, those with serious 
comorbidities, short life expectancy etc. The treatment goal regarding level of BG control is 
set individually (18). 
The patients need to be well educated in every aspect of insulin application from 
administration sites and amount of insulin to be administered in accordance to the consumed 
food to possible side effect of overdose with insulin that leads to hypoglycaemia. Patients are 
given glucagon injections that are administered intramuscularly in case of hypoglycaemic 
coma. Other possible way of administering insulin is via insulin pumps.  
These are arguably the most important parts of the patient education but one part that must not 
be forgotten is the lifestyle modifications that the patients has to go through. Balanced 
carbohydrates in the diet and exercise are necessary in DM type 1 to have best possible 
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results. Smoking should be avoided completely since it has heavy implication in increasing 
the risk of microvasculature damage that is already increased in diabetics. Alcohol should be 
consumed carefully and in moderation since it can make the management of a hypoglycaemic 
episode very difficult. Without the patient making an effort to implement these changes their 
glycaemic control is going to be suboptimal if not completely out of their control.  
Other possible treatment options are islet cell transplant and pancreas transplant. Both are not 
commonly used. There are many limitations to using these methods but the most notable one 
is immunosuppression. Generally the clinicians will not chose these options unless really 
necessary. 
3.7 Clinical case examples 
Case 1 
Male, born in 1941. Diabetes diagnosed in 2008 (67 years at the time of diagnosis). Family 
history is negative. Body mass stable, low. There was no symptoms of hyperglycaemia at 
diagnosis, HbA1c was 8.0%. After one year despite the three-drug therapy (metformin, 
gliclazide, pioglitazone) high glycemia, HbA1c up to 9%, for that reason it was initiated to 
begin with insulin in 2 doses. Glucoregulation is unstable, started basal - bolus therapy. GAD 
antibodies test performed- high titer. 
Diagnosis- type 1 diabetes with onset occuring in the older age. 
Case 2 
Female, born in 1991. Hospitalized in 2016 (24 years at the time of hospitalization) with 
uroinfection. After a month - two instances of polydipsia, weight loss (8 kg). At the time 
hyperglycemia (29 mmol / L) without acidosis. Started basal- bolus therapy but after 2 months 
interrupted after reducing insulin dose due to frequent hypoglycemia. ICA and GAD positive. 
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During 2018, due to the worsening of glucose regulation, insulin is gradually introduced, first 
with the bolus therapy. 
Diagnosis- type 1 diabetes with the honeymoon period. 
 
 
Case 3 
Male, born in 1976. Diabetes since 2017, due to high glycemic levels immediately initiated 
insulin treatment. 
From anamnesis: Alcoholism and anxiety syndrome from the mid-2000s. He was treated as a 
psychiatric patient, now he does not drink. On three occasions had acute pancreatitis episodes 
2014 - 2016. 
Diagnosis- ‖other” diabetes (pancreatic). 
4. Diabetes mellitus type 2 
Diabetes type 2 is a subtype of DM that is usually seen as high BG, insulin resistance and 
sometimes insulin deficiency. Lifestyle and an increasing trend of more and more people 
becoming obese might be the main culprits behind the pandemic that is DM type 2. 
4.1 Signs and symptoms 
Signs and symptoms of DM type 2 are quite similar to DM type 1 signs and symptoms. The 
notable difference is in how the disease is usually recognized. DM type 1 inadvertently leads 
to excessive and obvious symptomatology that usually hospitalizes the patient before it is 
discovered while DM type 2 most commonly has a more insidious onset and takes some time 
before being discovered.  
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This can be attributed to the fact that most patients have only a partial initial insulin resistance 
at least at the beginning of the pathology and not a complete one. Same can be said for the 
lack of insulin production, patient that is in the developing phase of the disease doesn’t 
necessarily have to have damage to the endocrine pancreas. For these reasons usual time and 
place of discovery of the DM type 2 happens in the setting of systematic check-ups. Usual 
presentation again attributable to hyperglycaemia is of polyuria, polydipsia, polyphagia and 
weight loss (19). Other symptoms can include but are not limited to dry mouth, fatigue, 
blurred vision, decreased vision, headaches, difficult to heal trauma, itchy skin, recurrent 
yeast infections, paraesthesia of hands and feet, etc. It is important to be aware of these 
symptoms to be able to discover the disease as early as possible.  
The sooner the treatment is implemented the better, since the risk of complications decreases 
due to decreased amount of time that the patient’s body has their homeostasis disrupted. 
4.2 Aetiology 
Development of DM type 2 cannot be attributed to a single process. Multitude of causative 
factors need to be taken into account when discussing the cause of this pathology. Main 
culprits behind the process are lifestyle habits, genetics and iatrogenic causes. Interestingly 
even lack of sleep has been attributed to the development of DM type 2 due to its adverse 
effects on the body (20).  
WHO also explains additional risks that may lead to DM type 2: ―Ethnicity, family history of 
diabetes, and previous gestational diabetes combine with older age, overweight and obesity, 
unhealthy diet, physical inactivity and smoking to increase risk. (2)‖  
Lifestyle factors such as sedentary lifestyle, obesity and being overweight, lack of physical 
activity, poor diet, stress, and urbanization all have an active role to play in the aetiology (21). 
Regarding genes involved in the development of DM type 2, we have accounted for 36 genes 
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which in turn translates to about 10% of the total heritable component of the disease (22). 
Iatrogenic causes include glucocorticoids, thiazides, beta blockers, atypical antipsychotics, 
etc. (23).  
Although genes and iatrogenic causes cannot be avoided the part that can be influenced the 
most is definitely lifestyle. However, it is more ―inheritable‖ than type 1 – concordance in 
monozygotic twins is 90% or more (24). If the habits of physical exercise and a properly 
regulated diet are implemented early enough in life it can reduce the risk of not only DM type 
2 but many other diseases. For these reasons the importance of the public health sector 
becomes apparent both for the clinicians and the population. 
4.3 Epidemiology 
In 2015 T. Vos, C. Allen, M. Arora, et al. estimated that there were 392 million people with 
type 2 diabetes making up about 90% of diabetes cases which means that about 6% of the 
human population suffers from this disease (25).  
DM type 2 in 1985 was estimated at 30 million, 135 million in 1995 and 217 million in 2005 
(26). Because of population aging and a sedentary lifestyle leading to increasing rates of 
obesity we see increased rates of this disease (26).  
Certain ethnic groups like South Asians, Pacific Islanders, Latinos, and Native Americans 
seem to be at an increased risk (19). Countries with the greatest number of people with 
diabetes as stated in ―Global prevalence of diabetes: estimates for the year 2000 and 
projections for 2030‖ are India having 31.7 million, China 20.8 million, the United States 17.7 
million, Indonesia 8.4 million, and Japan 6.8 million (27). This data shows us how much of a 
burden this particular disease is in the world and that it has pandemic proportions. 
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4.4 Pathophysiology 
While discussing the pathophysiology of DM type 2 we need to include insulin resistance and 
insulin secretion deficiency. This would be satisfactory to explain the main ideas behind the 
processes that lead to DM type 2. To get an even better understanding of the concept we also 
need to include the explanation of the feedback loop between the beta cells of the pancreas 
and the insulin sensitive tissues.  
Communication between the beta cells and the insulin sensitive tissues occurs through 
mediators that are yet to be determined. Insulin is responsible for enabling the uptake of 
glucose, amino acids and fatty acids into insulin-sensitive tissues while tissues respond letting 
the beta cells know how much insulin they need. For that reason in the setting of insulin 
resistance the beta cells are going to secrete more and more insulin. When the load becomes 
too great we see an elevation in BG. Further deterioration leads from prediabetes to frank DM 
type 2 (28).  
Many things cause tissues to become insulin resistant. Most common reason is insulin 
resistance occurring in the setting of obesity, other reasons include certain molecular 
mechanisms, genetic factors, diet, sedentary lifestyle and HCV.  
There seems to be a connection between the duodenum and insulin resistance in tissues. Some 
new small scale experimental research show that there might be a possible surgical 
intervention for non-obese related insulin resistance and DM type 2 (29), with more research 
we might get a new clue towards the exact reasons behind insulin resistance and development 
of DM type 2. 
4.5 Diagnosis 
The WHO criteria that are used for diagnosis of DM has been explained in section 3.5. of this 
thesis.  
16 
 
The difference that can help the clinicians in differentiating between these two pathologies is 
in the presenting circumstances. On one hand we have DM type 1 which presents quite soon 
after the onset of symptoms, on the other hand the course of DM type 2 is more insidious and 
takes more time to present with symptoms. DM type 2 often shows no symptoms, patients 
might contact their doctors because of complications or they can simply be diagnosed during 
routine check-ups (2). One potentially useful laboratory test in differentiating DM type 1 and 
2 is C-peptide levels. C-peptide levels, especially after a meal are low in type 1 diabetes and 
normal or high in type 2 diabetes (30).  
The key in better management of DM type 2 is early diagnosis. Although it is very important 
to discover the disease as soon as possible the question of performing or not performing 
screening for DM type 2 is still a heavily debated topic (2). 
4.6 Treatment plans and goals 
Treatment of DM type 2 encompasses lifestyle modifications, pharmacological management 
and surgery. While DM type 1 usually focuses on stricter BG controls the primary goal in DM 
type 2 management is a healthier lifestyle to control the cardiovascular risk factors. Since 
most patients that present with this disease have poor habits and are usually obese the idea is 
to educate them on how to change those habits and how to reduce weight.  
Smoking cessation and exercise help in improving hypertension. Current recommendation is 
to keep the systolic blood pressure between 140 to 150 mmHg. Keeping the systolic blood 
pressure below 140 mmHg is associated with lower morbidity and mortality (31). Diets like 
low glycaemic index diet or low carbohydrate diet can help improve BG (32).  
When discussing DM type 2 that is already an established disease that unfortunately cannot be 
managed purely with lifestyle modifications and pharmacological therapy needs to be 
instituted. First line therapy is metformin. Another class of medication or insulin may be 
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added if metformin is not controlling BGs acceptably after three months. Other classes 
include: sulfonylureas, thiazolidinedione’s, dipeptidyl peptidase-4 inhibitors, SGLT2 
inhibitors, and glucagon-like peptide-1 analogues (33). Angiotensin-converting enzyme 
inhibitors (ACEIs) help prevent kidney disease and improve outcomes in patients with 
diabetes (34). As a last step if oral medication is not sufficient to control BGs adding 
subcutaneous insulin injections help in management.  
In patients that have problems with controlling BGs and are unable to lose weight bariatric 
surgery is a viable option for managing diabetes (35). 
4.7 Clinical case examples 
Case 1 
Female, 55 years of age. Body mass decreasing, BMI 28. Has hypertension as a comorbidity. 
HbA1c 11.3%, hyperglycaemia 17.2 mmol/L and ketones of 0.1 mmol/L. DPP4 inhibitor and 
pioglitazone added. After 3 months body mass stable, HbA1c 6.3%. 
Diagnosis- type 2 diabetes. 
Case 2 
Female, 55 years of age. Body mass decreasing, BMI 21. Has no comorbidity. HbA1c 12.0%, 
hyperglycaemia 18.5 mmol/L and ketones of 0.7 mmol/L. Gliclazide added, possible initiation 
of insulin considered. However, the patient came after 3 months with increased body mass 
and HbA1c 6.5%. GAD was tested and revealed a negative result. 
Diagnosis- type 2 diabetes. 
Case 3 
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Male, 62 years of age. Body mass decreasing, BMI 29. Has hypertension as a comorbidity and 
he is also a cardiology patient. HbA1c 12.0%, hyperglycaemia 20.0 mmol/L. Metformin 
added. After 3 months body mass decreased, HbA1c 6.3%. 
Diagnosis- type 2 diabetes. 
Case 4 
Female, 74 years of age. Body mass stable, BMI 29. Has hypertension as a comorbidity, had a 
cerebrovascular insult and cardiac decompensation. HbA1c 10.9%, hyperglycaemia 27.2 
mmol/L and ketones of 0.1 mmol/L. Gliklazid and metformin added. After 3 months body 
mass stable, HbA1c 6.2%. 
Diagnosis- type 2 diabetes. 
5. Other rare types 
5.1 MODY 
Maturity onset diabetes of the young is one of the rare types of diabetes and has an autosomal 
dominant inheritance due to a mutation in one gene. Only about 1-2% of diabetes cases are 
attributed to MODY. Since the education of general practitioners for these less common types 
of diabetes is still lacking it is estimated that up to 90% percent of MODY cases are either 
diagnosed as DM type 1 or 2.  
Some of the key features of MODY are; patients are diagnosed before they are 25 years of 
age, have a family history of diabetes for at least 2 generations and they don’t necessarily 
require insulin treatment.  
Subtypes of MODY have different gene mutations and the most common mutations are on 
genes: HNF1-alpha, HNF4-alpha, HNF1-beta and glucokinase (36). It is important to 
recognize that the patient has MODY since the treatment is going to differ in subtypes of the 
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disease. Being aware which subtype it is helps in advising the patients on what to expect and 
also to help prepare them for family planning. 
5.1.1 Clinical case example 
Case 1 
Male, born in 1990. Diabetes from 2014 (24 years at the time of initial diagnosis). No 
symptoms, high glycaemia (17mmol / L) observed on a check-up for mycosis treatment, 
HbA1c was 9.1%. Mother and grandmother have diabetes, they do not take insulin, mother's 
sister takes insulin from the time of her diagnosis. Started with insulin in the basal- bolus 
scheme. The dose gradually decreased. ICA and GAD negative. There is suspicion for 
monogenetic diabetes. HNF4- alpha positive. Started with a low dose of gliclazide, HbA1c is 
6.5%. 
Diagnosis- MODY 1 
5.2 LADA 
Latent autoimmune diabetes in adults is a form of DM type 1 that develops later in life. Prof. 
David Leslie, defines LADA as: ―initially non-insulin requiring diabetes diagnosed in people 
aged 30-50 years with antibodies to GAD - glutamic acid decarboxylase‖ (37).  
Once more the problem of insufficient education is one of the culprits behind the fact that 
most cases of LADA are misdiagnosed as DM type 2. Symptoms of LADA are quite similar 
to DM type 2 and thus lead to the wrong diagnosis. With progression of the disease deficiency 
of insulin becomes more pronounced and starts exhibiting similar symptoms to DM type 1.  
A study done in the UK found that antibodies specific to LADA cases are found in about 8% 
of DM cases (37). With lifestyle modification it is possible to postpone the need for insulin 
treatment but the treatment itself is inevitable. 
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5.2.1 Clinical case example 
Case 1 
Male, born in 1981. Diabetes discovered in 2007 (26 years at the time of diagnosis). Father 
has type 2 diabetes. BMI at the time of diagnosis was 25, body mass stable. There were no 
symptoms, HbA1c was 7.0%. GAD and IA2 positive. Received insulin once, but with diet and 
metformin achieved the ideal glucoregulation, HbA1c about 6% by 2013. Gained weight 
(BMI up to 31). Because of the worsening of glucose regulation, basal insulin (detemir) with 
DPP4 (sitagliptin) and metformin added in 2013. Wasn’t adhering to therapy, last control in 
2015 after a prolonged period of time – stoped taking insulin, metformin taken regularly, 
body mass too high (BMI 30), HbA1c 6.5%. 
Diagnosis- LADA. 
 
6. Conclusion 
Diabetes is a special challenge for patients, their families, clinicians, public health workers 
and the society as a whole. For many years now a lot of effort has been put into researching 
all aspects of the disease from its aetiology to the optimal treatment methods for all types of 
diabetes. Although we still don’t have the complete picture of every aspect of diabetes we 
made great strides forward in improving both morbidity and mortality of diabetes patients. 
The life expectancy for diabetic patients is coming closer and closer to that of the healthy 
population.  
Probably the most important idea that needs elaboration is that diabetes treatment is not 
necessarily a rigid, inflexible set of rules and needs to be tailored to the individual and not the 
disease. An appropriate example of that would be that in DM type 1 patients the most 
common basal- bolus scheme for insulin is 50-50% but in some cases such a scheme could be 
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counterproductive. If the patient has a lifestyle where he or she eat multiple times a day and 
possibly see that they have better glucose control on a basal- bolus scheme of 40-60% they 
should be able and allowed to do so, to accommodate the disease to their lifestyle and not the 
other way around. Likewise, in any other type of diabetes if the patient is not in complete 
accordance to the guidelines but they have good glucose regulation and their HbA1c levels 
are satisfactory they should be enabled and feel that they can ask for advice on their actions 
from the physicians. 
In conclusion, we should strive for improvement in every aspect of the disease and hopefully 
as the end goal we will be able to not only improve patient’s lives but to cure diabetes. 
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